The delisting is the final step in the going-private transaction. Shareholders who tendered their shares have already received the $3.16 per share cash consideration plus CVRs. No further trading in ESPR common stock is expected. Monitor CVR milestone events for potential additional value.
ESPR drugs
ESPR drug pipeline →Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Esperion Therapeutics has been delisted from Nasdaq following its acquisition by ArchiMed (via Essence Parent Inc.) for $3.16 per share plus CVRs. The 25-NSE filing formalizes the removal of the company's common stock from listing and SEC registration, effective July 13, 2026. This is the final procedural step in the going-private transaction, and the stock will no longer trade on Nasdaq.
Key Facts
- Esperion Therapeutics completed its acquisition by ArchiMed (via Essence Parent Inc.) on July 13, 2026, for $3.16 per share in cash plus one CVR per share representing up to $100M in aggregate milestone payments.
- The 25-NSE filing formalizes the removal of Esperion's common stock from listing and registration on Nasdaq, effective July 13, 2026.
- The delisting follows a change of control, board replacement, and termination of the prior credit agreement with new debt financing from BioPharma Credit.
- The filing is made under Rule 17 CFR 240.12d2-2(a)(3), which covers securities that have been redeemed, retired, or matured.
Financial Impact
Shareholders received $3.16 per share in cash plus one CVR per share representing up to $100M in aggregate milestone payments. The stock will be delisted and no longer trade on Nasdaq.
Risk Factors
- CVR milestone payments are contingent and may not be achieved, resulting in no additional value beyond the $3.16 per share.
- The stock is now delisted and illiquid; remaining public shareholders must seek liquidity through the merger consideration process.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 25-NSE Filing (Primary) | 0001354457-26-000668 |
| Document: 0001354457-26-000668-index-headers.html | 0001354457-26-000668 |
| Document: 0001354457-26-000668-index.html | 0001354457-26-000668 |
| Document: 0001354457-26-000668.txt | 0001354457-26-000668 |
Track record
21 reports on ESPR
4 of 7 bullish or bearish reports moved the stock their way by T+20. Best: +16.30% at T+60 after the Mar 10, 2026 report. 6 of 8 went positive at some point.
Filters
- Nov 10, 20266d ago SC 13G/A Bearish 4/10 No price data
- Sep 3, 202610w ago Court Ruling Bullish 5/10 No price data
- Aug 13, 202613w ago Institutional Cluster Bearish 5/10 No price data
- Jul 23, 202616w ago 15-12G Neutral 5/10 No price data
- Jul 16, 202617w ago EFFECT Bearish 5/10 Entry $3.18 No price data
- Jul 16, 202617w ago EFFECT Bearish 5/10 Entry $3.18 No price data
- Jul 13, 202618w ago 25-NSE Bullish 7/10 Viewing Entry $3.19 No price data
- Jul 13, 202618w ago 8-K Bullish 7/10 Entry $3.19 No price data
- Jun 16, 202621w ago DEFA14A Bullish 6/10 Entry $3.17 No price data
- Jun 11, 202622w ago Institutional Cluster Mixed 4/10 Entry $3.15 to $3.19 ▲ +1.27% −0.62% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers